Royalty Report: Drugs, Viral Infection, Disease – Collection: 288103


Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 3

Primary Industries

  • Drugs
  • Viral Infection
  • Disease
  • Drug Discovery
  • Assay
  • Diagnostic
  • Molecular

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 288103

License Grant
The Licensor group, including Universities, grants an exclusive license agreement to patents for new drug development.

During the term of the license agreement and for two years thereafter, Licensee undertakes not to develop or commercialize any product that directly competes with any marketed product that is covered by the licensed technology.

License Property
The intellectual property is for NLS-1. a small molecule candidate, derived from natural products, for treatment of viral infections caused by influenza virus A.

With this agreement, Licensee became the exclusive licensee of 6 U.S. patents, 1 European Patent, 1 PRC patent, 1 Indian patent and 1 Japanese patent, as well as 1 pending US patent application. Two technologies are claimed in the patents: Epigallocatechin Gallate Derivatives for Inhibiting Proteasome, and Pro-EGCG.

Field of Use
NLS-1 is under active development for the treatment of endometriosis.

Endometriosis is an often painful disorder in which tissue similar to the tissue that normally lines the inside of your uterus — the endometrium — grows outside your uterus. Endometriosis most commonly involves your ovaries, fallopian tubes and the tissue lining your pelvis.

IPSCIO Record ID: 255484

License Grant
Licensor grants an irrevocable, limited, exclusive, world-wide license to use Companion Diagnostic Tests as the rationale for and as an on-label indication for Endometriosis Therapeutic.
License Property
LICENSOR is engaged in the development of genetic tests for the determination of the existence and the predisposition of endometriosis and related conditions.

LICENSOR is the named assignee for several patent applications including nonprovisional US patent application SIN 12/120,322 to Kenneth Ward entitled 'Method of Administering a Therapeutic'.

Companion Diagnostic Tests mean any Test for the administration of a Therapeutic, the use, sale, or offer of sale of which would, but for this Agreement, constitute an infringement of the Patent Application referred to as 322 or any continuation, divisional, continuation in part, or foreign counterpart application claiming priority to the 322 Application, and any patent that may issue therefrom, collectively, the Test Patents.

Endometriosis is an often painful disorder in which tissue that normally lines the inside of your uterus — the endometrium — grows outside your uterus. Endometriosis most commonly involves your ovaries, fallopian tubes and the tissue lining your pelvis.

Field of Use
The field of use application is for the commercialization of assays and related services for the prediction of endometriosis, and other health concerns, in the infertility market.

IPSCIO Record ID: 283093

License Grant
Licensor granted an exclusive, sublicensable license to develop, make, have made, use, sell, offer for sale and import products that are covered by the licensed patents to ALS-1.
License Property
ALS-1is a Small molecule intended for the treatment of viral infections caused by Influenza virus A.  ALS-1 is designed to target a broad range of NP variants, a novel therapeutic target.

The patent claimed invention is described as Antiviral Compounds and Methods of Making and Using Thereof.

Field of Use
The field of the license is for treatment or prevention of viral infections including influenza.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.